Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status

Phase III, open-label, single-center, controlled study in South Africa (ClinicalTrials.gov: NCT00829010) to evaluate immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2017-01, Vol.96 (2), p.e5881-e5881
Main Authors: Madhi, Shabir A, Koen, Anthonet, Jose, Lisa, van Niekerk, Nadia, Adrian, Peter V, Cutland, Clare, François, Nancy, Ruiz-Guiñazú, Javier, Yarzabal, Juan-Pablo, Moreira, Marta, Borys, Dorota, Schuerman, Lode
Format: Article
Language:English
Subjects:
Antibodies, Bacterial - blood
Bacterial Proteins - immunology
Carrier Proteins - immunology
Clinical Trial/Experimental Study
HIV Infections
Humans
Immunization, Secondary
Immunoglobulin D - immunology
Immunoglobulin G - blood
Infant
Lipoproteins - immunology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - adverse effects
Pneumococcal Vaccines - immunology
South Africa
Vaccination - adverse effects
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - adverse effects
Vaccines, Conjugate - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phase III, open-label, single-center, controlled study in South Africa (ClinicalTrials.gov: NCT00829010) to evaluate immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV)-infected (HIV+), HIV-exposed-uninfected (HEU), and HIV-unexposed-uninfected (HUU) children. Children stratified by HIV status received PHiD-CV primary vaccination (age 6/10/14 weeks; coadministered with routine childhood vaccines) and booster dose (age 9-10 months). Immune responses, assessed using enzyme-linked immunosorbent and functional assays, and safety were evaluated up to 14 months post-booster. Of 83, 101, and 100 children enrolled in HIV+, HEU, and HUU groups, 70, 91, and 93 were included in according-to-protocol immunogenicity cohort. For each vaccine-serotype, percentages of children with antibody concentrations ≥0.2 μg/mL were ≥97% 1 month post-primary vaccination and ≥98.5% 1 month post-booster (except for 6B and 23F at both timepoints). Post-primary vaccination, functional antibody responses were lower in HIV+ children: for each vaccine-serotype, percentages of children with opsonophagocytic activity (OPA) titres ≥8 were ≥72%, ≥81%, and ≥79% for HIV+, HEU, and HUU children. Post-booster, ≥87% of children in each group had OPA titres ≥8. Reactogenicity was similar across groups. Thirty one (37%) HIV+, 25 (25%) HEU, and 20 (20%) HUU children reported ≥1 serious adverse event. Five HIV+ and 4 HEU children died. One death (sudden infant death syndrome; HEU group; 3 days post-dose 1) was considered potentially vaccine-related. PHiD-CV was immunogenic and well-tolerated in HIV+, HEU, and HUU children, and has the potential to provide substantial benefit irrespective of HIV infection status.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000005881